1. Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan

2. Genomics Commercialization: Drug Timeline The Canadian Biopharmaceutical Industry Technology Roadmap 30%

3. Stage Percentage Discovery 25 Preclinical 7 Phase I 7 Phase II 11 Phase III 23 Regulatory Approval 12 Phase IV (Post Marketing) 11 Uncategorized 4 R&D Drug Investment by Function Pharmaceutical Research and Manufacturers of America, Annual Membership Survey, 2003 Drug discovery = 25% of R&D costs and 45% of development time. Tools such as genomics, bioinformatics, etc. have had minimal impact on R&D productivity when measured by the number of drugs that have entered clinical trials and moved to regulatory approval.

5. Genomics Commercialization

6. Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan